Hallucinations and dyskinesia with pramipexole in parkinson’s disease-a case report


  • Monica Aggarwal Department of Pharmacology, ESIC Medical College and Hospital, NH3 Faridabad, India
  • Brahmdeep Sindhu Department of Psychiatry, Civil Hospital, Gurgaon, India




Pramipexole, Parkinson’s disease, Dyskinesia, Hallucinations


Pramipexole, a dopamine agonist has a tendency to induce psychotic symptoms, when used to treat Parkinson’s disease (PD). In most of the cases, patient’s psychosis developed after addition of Pramipexole and exacerbated after increasing the dosage. However there has been no case report in which Pramipexole has caused psychosis at lowest starting dose without any add on drug. Here we present a case of PD in which dyskinesia and psychosis appeared with first dose of Pramipexole, as low as 0.125mg. The patient was a 76 year old man with a one year history of PD. One year back patient observed tremors in his hand and slowing of movements. The neurologist prescribed Syndopa plus - 125, Benzhexol (schedule also same as Syndopa) and Pramipexole 0.125 mg at bedtime. The patient decided to start all medicines next day except Pramipexole (125mg) which he took at bed time. Within half an hour, patient started having visual and auditory hallucinations, along with abnormal movements and myoclonic jerks of hand, feet and mouth. He could be seen doing movements as if he is inserting needle in thread. According to him, he could visualize thieves trying to steal his car. Dechallenge with Pramipexole led to complete resolve of psychotic symptoms. After 4 weeks of therapy, there was a gradual but steady improvement in dyskinesia and tremors except slurring in speech.


Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol. 1992;215:161-70.

Svensson K, Carlsson A, Huff RM. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol. 1994;263:235-43.

Mierau J. Pramipexole: a dopamine-receptor agonist for treatment of Parkinson’s disease. Clin Neuropharmacol. 1995;18(Suppl 1):S195-S206.

Bennett JP, Piercey MF. Pramipexole - a new dopamine agonist for the treatment of Parkinson’s disease. J Neurol Sci. 1991;163:25-31.

Bouthenet ML, Souil E, Martres MP. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 1991;564:203-19.

Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease: a meta-analysis. Drug Safety. 2003;26:439-47.

Cheng-Ta Li, Tsai S, Hwang JP. Pramipexole-induced psychosis in Parkinson's disease. Psychiatry and Clinical Neurosciences. 2008;62:245.

Parkinson Study Group. Pramipexole versus levodopa as initial treatment for parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931-8.

Shannon KM, Bennett JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurol. 1997;49:724-8.

Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced parkinson’s disease: results of a double-blind, placebo controlled, parallel-group study. Neurol. 1997;49:162-8.

Moller JC, Oertel WH, Koster J. Long-term efficacy and safety of pramipexole in advanced parkinson’s disease: results from a European multicenter trial. Mov Disord. 2005;20:602-10.

Mizuno Y, Yanagisawa N, Kuno S. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. Mov Disord. 2003;18:1149-56.

Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergotine dopamine agonist pramipexole in the treatment of advanced parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999;66:436-4.

Holloway RG, Shoulson I, Fahn S. Pramipexole versus levodopa as initial treatment for parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044-53.

Kieburtz K. Safety and efficacy of pramipexole in early parkinson disease: a randomized dose-ranging study. JAMA. 1997;278:125-30.

Hauser RA, Schapira AH, Rascol O. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early parkinson’s disease. Mov Disord. 2010;25:2542-9.

Rascol O, Barone P, Hauser RA. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early parkinson’s disease. Mov Disord. 2010;25:2326-32.

Holloway R, Marek K, Biglan K. Long-term effect of initiating pramipexole versus Levodopa in early Parkinson disease. Arch Neurol. 2009;66:563-70.




How to Cite

Aggarwal, M., & Sindhu, B. (2017). Hallucinations and dyskinesia with pramipexole in parkinson’s disease-a case report. International Journal of Basic & Clinical Pharmacology, 5(5), 2276–2279. https://doi.org/10.18203/2319-2003.ijbcp20163275